Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable

, &
Journal of Law, Medicine and Ethics 52 (1):188-190 (2024)
  Copy   BIBTEX

Abstract

Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2024.56

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 101,551

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.Ezekiel J. Emanuel, Johan L. Dellgren, Matthew S. McCoy & Govind Persad - forthcoming - New England Journal of Medicine.
International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.Johan Dellgren, Govind Persad & Ezekiel J. Emanuel - 2024 - The Lancet 404 (10455):902-906.
Ethical Approaches to Limiting Overall Costs for Glucagon-Like Peptide-1 Receptor Agonists for Weight Management.Johan Dellgren, Ezekiel Emanuel & Govind Persad - forthcoming - Annals of Internal Medicine.
The Ethics of Ozempic and Wegovy.Nanette Ryan & Julian Savulescu - forthcoming - Journal of Medical Ethics.
Medicare Drug Pricing Negotiations: Assessing Constitutional Structural Limits.Erica N. White, Mary Saxon, James G. Hodge & Joel Michaels - 2023 - Journal of Law, Medicine and Ethics 51 (4):956-960.
The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.Raj Bhargava, Nathan Brown, Amy Kapczynski, Aaron S. Kesselheim, Stephanie Y. Lim & Christopher J. Morten - 2023 - Journal of Law, Medicine and Ethics 51 (4):961-971.
Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries.Edward R. Balotsky - 2009 - Journal of Business Ethics 84 (S1):75 - 88.
Medicaid & Medicare: HCFA must monitor HMOs to ensure appeal rights for Medicare beneficiaries.Jess Alderman - 1998 - Journal of Law, Medicine and Ethics 26 (3):253.
Use of Public Research and Manufacturing Enterprises to Lower Prescription Drug Prices and Increase Innovation.Alex Moss, Dana Brown & S. Sean Tu - 2024 - Journal of Law, Medicine and Ethics 52 (3):750-754.
Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part D.J. Yazdany, R. A. Dudley, R. Chen, G. A. Lin & C. W. Tseng - unknown

Analytics

Added to PP
2024-06-02

Downloads
12 (#1,374,231)

6 months
8 (#597,840)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references